Interview Elias Jabbour- Advances in Survival and Immunotherapy

Elias Jabbour, MD discussed a significant healthcare revolution at a recent conference, highlighting the remarkable shift from a ten percent ten-year survival rate to a ninety percent four to five-year survival rate.

0:00:56

MD-Education

3 months 18 Views

elias jabbour 4

MD-Education 73

AML-ALL US Focus Meeting 2023 72

immunotherapy 16

Share Add to Report 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/channel/MDEducation/videoEmbed/42355/interview-elias-jabbour--advances-in-survival-and-immunotherapy?modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/channel/MDEducation/videoEmbed/42355/interview-elias-jabbour--advances-in-survival-and-immunotherapy?modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/channel/MDEducation/videoEmbed/42355/interview-elias-jabbour--advances-in-survival-and-immunotherapy?modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/channel/MDEducation/video/42355"><img src="https://oncologytubecom.cdn.ypt.me/view/img/video-placeholder-gray-portrait.webp?cache=1693571832_1693571832">Interview Elias Jabbour- Advances in Survival and Immunotherapy</a>

Link (BBCode):

[url=https://oncologytube.com/channel/MDEducation/video/42355][img]https://oncologytubecom.cdn.ypt.me/view/img/video-placeholder-gray-portrait.webp?cache=1693571832_1693571832[/img]Interview Elias Jabbour- Advances in Survival and Immunotherapy[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Acute Lymphoblastic Leukemia

Description:

Elias Jabbour, MD - Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX

Elias Jabbour, MD a dedicated professional at MD Anderson in Houston, Texas, recently presented groundbreaking insights at a conference. Formerly dire disease survival rates have been revolutionized, with ten-year survival now at an impressive ninety percent within four to five years. This transformation represents a new standard of care and a remarkable advancement for patients.

AML-ALL US - Online content available - https://aml-allus2023.md-education.com/register/

AML-ALL EU - Registration open - https://aml-alleu2023.md-education.com/register/

MPN-MDS EU - registration open - https://mpn-mdseu2023.md-education.com/register/

aml-allus2023.md-education.com

Elias Jabbour, MD also highlighted the promising role of immunotherapy in a laboratory setting, emphasizing the collaborative potential of various tools to enhance outcomes. The conference, characterized by engaging discussions, research exploration, and networking, left attendees invigorated and inspired.